N1-methylpseudouridine is a chemically modified version of one of RNA’s four standard building blocks, and it is the single modification most responsible for making mRNA vaccines work in practice. Every dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines contains mRNA in which every uridine has been swapped out for this synthetic stand-in, a change that quietly solved two problems researchers had struggled with for decades: the body’s tendency to destroy injected mRNA before it can do anything useful, and its tendency to mount an inflammatory alarm against the foreign molecule. The story of how a small methyl group added to a naturally occurring RNA modification transformed vaccine science is more layered than most people realize.
What N1-Methylpseudouridine Actually Is
RNA is built from four nucleosides: adenosine, guanosine, cytidine, and uridine. Pseudouridine is a naturally occurring variant of uridine found throughout human cells, particularly in ribosomal RNA and transfer RNA. The difference is subtle: the bond connecting the base to the sugar is rearranged from a nitrogen-carbon link to a carbon-carbon link. N1-methylpseudouridine (often abbreviated m1Ψ) takes that one step further by attaching a methyl group at a specific position on the base. That extra methyl group turns out to have outsized biological consequences.
When scientists manufacture mRNA in the lab for vaccines or therapies, they can substitute m1Ψ for every uridine in the sequence. The resulting mRNA looks and functions enough like natural mRNA that ribosomes can still read it and produce the encoded protein, but it behaves differently enough that the immune system’s frontline sensors largely ignore it. This dual property, functional to the cell’s protein-making machinery but invisible to its alarm systems, is what makes m1Ψ so valuable.1PubMed Central. Pseudouridine and N1-methylpseudouridine as potent nucleotide analogues for RNA therapy and vaccine development
How It Slips Past the Immune System’s Sensors
Your cells are wired to treat foreign RNA as a threat. Viruses deliver their genetic material as RNA, so the immune system has evolved multiple layers of surveillance to catch it. The problem for mRNA vaccine developers is that lab-made mRNA triggers the same alarms. Unmodified mRNA injected into a person activates sensors called Toll-like receptors, which sit inside cellular compartments and scan for molecular patterns associated with pathogens. When these receptors fire, they launch an inflammatory cascade that chews up the mRNA and suppresses the cell’s protein-making machinery, exactly the opposite of what a vaccine needs.
M1Ψ-containing mRNA largely evades this surveillance. Studies in cell lines and mice have shown that it avoids triggering Toll-like receptor 3, one of the key sensors for double-stranded RNA patterns, and that this evasion accounts for at least part of its dramatically higher protein output compared to unmodified mRNA.2PubMed. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice Cancer immunotherapy research has also identified that m1Ψ helps mRNA dodge detection by Toll-like receptors 7 and 8, which specialize in sensing single-stranded RNA.3PubMed Central. Leveraging mRNA technology for antigen based immuno-oncology therapies
The evasion does not stop at Toll-like receptors. Cells also have cytoplasmic sensors, including a protein called PKR that detects double-stranded RNA structures and shuts down translation when it finds them. Unmodified mRNA can form transient secondary structures that trip PKR, but pseudouridine-containing transcripts cause minimal PKR activation and maintain higher protein output.4Meditory. Pseudouridine and N1-methylpseudouridine in mRNA vaccines modulate Retinoic Acid Inducible Gene I (RIG-I) and Toll-Like Receptors (TLR) activation Researchers have also found that m1Ψ evades immune detection partly because the modification interferes with the enzymes that normally chop up RNA inside cellular compartments, slowing the processing that would otherwise expose fragments to immune sensors.5Immunology Research and Perspectives. N1-Methylpseudouridine as a Molecular Regulator of mRNA Vaccine Immunogenicity and Translation Efficiency
The Interferon Question
One of the clearest demonstrations of how m1Ψ changes the immune response comes from looking at interferons, the signaling molecules cells release when they detect a viral threat. In a head-to-head comparison, cells treated with standard uridine-containing mRNA cranked out type I and type III interferons along with more than a dozen downstream immune genes. Cells treated with m1Ψ-modified mRNA encoding the same protein produced essentially none of that response.6PubMed Central. Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine
This suppression extends to inflammatory cytokines. In human macrophages, m1Ψ modification led to significantly lower secretion of TNF-alpha and IL-6, two proteins that drive fever, swelling, and the general feeling of being sick after a vaccination. Interferon-beta secretion was also reduced, though the suppression was not absolute: at high mRNA doses measured over 24 hours, some interferon-beta production crept back.7Molecular Therapy Nucleic Acids. Systematic analysis of chemical modifications of in vitro-transcribed mRNA on primary human macrophage cellular response The practical upshot: m1Ψ-modified vaccines still provoke enough immune response to generate protective antibodies (that is the whole point), but they dial down the nonspecific inflammatory noise that would otherwise degrade the mRNA and make the recipient feel worse than necessary.
Why It Makes Cells Produce More Protein
Dodging immune sensors is only half the story. M1Ψ also makes the protein-production machinery work harder. Research has shown that mRNA containing m1Ψ attracts more ribosomes per molecule and that these ribosomes pack more tightly along the strand, increasing the rate at which they initiate translation. Part of this boost comes from reduced activation of PKR, which otherwise puts the brakes on translation. But there also appears to be an independent effect: the modification itself seems to make the mRNA more attractive to the initiation machinery.8PubMed Central. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density
The numbers are striking. When compared directly to pseudouridine (the “parent” modification that occurs naturally in cells), m1Ψ-modified mRNA produced roughly 13-fold more protein in mice and up to about 44-fold more in cell lines when combined with another modification.9PubMed. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice The structural reason likely involves the methyl group’s effect on how the bases stack and pair within the RNA strand, altering its flexibility and thermodynamic stability in ways that depend on the surrounding sequence context.10ChemistrySelect. Structural and Thermodynamic Consequences of Base Pairs Containing Pseudouridine and N1‐methylpseudouridine in RNA Duplexes
The Frameshifting Wrinkle
No modification is perfect, and m1Ψ introduced a concern that made headlines in 2023: ribosomal frameshifting. Ribosomes read mRNA in groups of three nucleotides at a time. If a ribosome slips forward by one nucleotide (a “+1 frameshift”), it starts reading a completely different set of instructions, producing scrambled protein fragments. Research found that m1Ψ can promote low levels of +1 frameshifting on COVID-19 vaccine sequences, likely because the modification subtly slows down how ribosomes decode certain positions.11PubMed Central. N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation
The same research showed that m1Ψ can alter the accuracy of amino acid selection in a way that depends heavily on the surrounding sequence and which transfer RNA is involved. In some codon contexts, m1Ψ slightly increased the production of incorrectly coded peptides, while in others it had no effect or even improved accuracy. The effects were described as low-level and context-dependent rather than catastrophic, but they raised an important design question: could vaccine sequences be optimized to minimize frameshifting at positions where m1Ψ causes problems? Vaccine manufacturers have since focused on codon optimization strategies that avoid the sequence contexts most prone to slippage. The frameshifted peptides produced in practice appear to be cleared by the immune system without harm, but this remains an active area of investigation.
How It Compares to Other Modifications
M1Ψ is not the only modified nucleoside researchers have tried. A systematic comparison of several modifications found that m1Ψ, 5-methoxyuridine (5moU), and pseudouridine were the top three performers for protein expression across multiple cell lines.12PubMed. Effects of Chemically Modified Messenger RNA on Protein Expression Interestingly, 5moU-modified mRNA was more stable than the others and completely prevented TNF-alpha and IL-6 induction, even outperforming m1Ψ on those particular inflammatory markers.13Molecular Therapy Nucleic Acids. Systematic analysis of chemical modifications of in vitro-transcribed mRNA on primary human macrophage cellular response So why did m1Ψ become the standard rather than 5moU?
The answer lies in the balance of properties needed for a vaccine specifically. A vaccine needs the immune system to respond, just not to the mRNA delivery vehicle itself. M1Ψ hits a sweet spot: it suppresses the innate inflammatory response enough to protect the mRNA and let protein production proceed, but it does not suppress immune activation so completely that the adaptive immune response (the antibody and T-cell response you actually want) is compromised. A modification that is too good at hiding from the immune system might produce plenty of protein but fail to generate lasting immunity. The interplay between mRNA modification and the lipid nanoparticle delivery system also matters, as studies in primates have demonstrated that the combination of m1Ψ-modified mRNA with specific lipid nanoparticle formulations dramatically reduced innate chemokine and cytokine production compared to unmodified mRNA in the same carriers.14Molecular Therapy Nucleic Acids. Interplay between N1-methylpseudouridine modification of mRNA and lipid nanoparticle composition in determining vaccine performance
The COVID-19 Vaccine Proof of Concept
The most visible demonstration of m1Ψ’s value came during the pandemic. Both the Pfizer-BioNTech and Moderna COVID-19 vaccines used m1Ψ-modified mRNA encoding the SARS-CoV-2 spike protein, delivered in lipid nanoparticles.15PubMed Central. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines A third mRNA vaccine candidate, CureVac’s CVnCoV, used unmodified uridine instead. The efficacy difference was dramatic: the Pfizer and Moderna vaccines achieved roughly 95% efficacy in their pivotal trials, while CVnCoV reached only about 48%. While multiple design differences existed between the vaccines, the absence of m1Ψ modification in CVnCoV has been identified as a key factor in its lower performance.16PubMed Central. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines
That comparison, playing out in real time during a global health emergency, essentially settled a debate that had been simmering in the mRNA field for years. The question was no longer whether nucleoside modifications mattered, but how to use them optimally.
The Nobel Prize and the Research That Led Here
In 2023, Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine for their work on nucleoside base modifications that enabled mRNA vaccine development. Their key insight, published in the mid-2000s, was that replacing uridine with pseudouridine (and later m1Ψ) could prevent the immune system from attacking therapeutic mRNA. The Nobel committee recognized this as the breakthrough that overcame one of the major obstacles to practical mRNA medicine: the recognition of foreign mRNA by endosomal Toll-like receptors and the resulting immune destruction.17Journal of Medical Science. The pivotal role of uridine modifications in the development of mRNA technology
The prize was well deserved, but the history is worth understanding in broader context. The research that made mRNA vaccines possible spanned over 40 years and involved contributions from many groups, from the early work on in vitro transcription to the development of lipid nanoparticle delivery systems. Karikó and Weissman’s modification work was the piece that made all the other pieces suddenly viable, but it did not arise in isolation.
Beyond Vaccines
The same properties that make m1Ψ useful for vaccines are being explored for protein replacement therapies, where the goal is to get the body to produce a protein it cannot make on its own due to a genetic defect. Conditions like cystic fibrosis, certain enzyme deficiencies, and rare metabolic disorders are all potential targets. The advantage of m1Ψ-modified mRNA over traditional protein infusions is that it lets the body’s own cells produce the protein, fold it correctly, and deliver it to the right cellular compartments, something that is difficult to achieve by injecting a pre-made protein.
Cancer immunotherapy is another frontier. Researchers are designing mRNA vaccines that encode tumor-specific neoantigens, the mutant proteins found on cancer cells but not normal tissue. The idea is to train the immune system to recognize and attack cells displaying those proteins. M1Ψ modification plays the same role here as in infectious disease vaccines: it protects the mRNA long enough for it to be translated into protein, while keeping the inflammatory response from overwhelming the therapeutic signal.18PubMed Central. Leveraging mRNA technology for antigen based immuno-oncology therapies Clinical trials for personalized cancer vaccines using this approach are underway for melanoma, pancreatic cancer, and several other tumor types.
Manufacturing Challenges
One underappreciated aspect of m1Ψ is that it is expensive and complicated to produce. The raw material needed is m1Ψ triphosphate, the activated form that RNA polymerase can incorporate into a growing mRNA strand. Traditional chemical synthesis routes are multi-step and generate significant waste. Recent work has developed more efficient production methods, including a chemoenzymatic approach that uses yeast and bacterial enzymes in a cascade to convert simpler precursors into m1Ψ triphosphate at around 200-milligram scale with improved efficiency and sustainability compared to purely chemical methods.19Angewandte Chemie International Edition. Integrated Chemoenzymatic Synthesis of the mRNA Vaccine Building Block N(1)-Methylpseudouridine Triphosphate
Scaling this up from milligrams to the kilograms needed for global vaccine production is a substantial engineering challenge. During the COVID-19 pandemic, the supply chain for modified nucleosides was one of the bottlenecks limiting how fast vaccines could be manufactured. Multiple companies and academic groups are working on streamlined production routes that could bring costs down and make mRNA therapeutics accessible in lower-income settings where current pricing is prohibitive. The intellectual property landscape around m1Ψ is also complex, with overlapping patents held by different institutions, which has created licensing complications for companies trying to develop new mRNA products.
When Hiding From the Immune System Is Not What You Want
There is an irony at the heart of m1Ψ’s success that researchers are still working through. For a vaccine, you need the immune system to respond. M1Ψ suppresses the innate immune response to the mRNA itself, which is helpful, but innate immune activation also serves as a natural adjuvant that helps kick-start the adaptive immune response you actually want. By dampening the innate alarm, m1Ψ might be reducing some of the adjuvant effect that comes for free with unmodified mRNA.
This is why the lipid nanoparticle matters so much. The lipid carrier provides its own form of immune stimulation, partially compensating for what m1Ψ takes away. Research in primates showed that the specific lipid nanoparticle formulation interacted with the mRNA modification status to determine the overall immune profile: animals receiving m1Ψ-modified mRNA had drastically lower inflammatory cytokine levels than those receiving unmodified mRNA in the same carrier, but still mounted antibody responses.20Molecular Therapy Nucleic Acids. Interplay between N1-methylpseudouridine modification of mRNA and lipid nanoparticle composition in determining vaccine performance Getting this balance right for each new vaccine target, enough immune stimulation to generate strong protection without so much inflammation that the mRNA is destroyed, remains as much art as science. For some future applications, particularly in settings where a strong innate response is actually desirable, researchers are exploring partial m1Ψ incorporation or blends of modified and unmodified nucleosides rather than complete substitution.